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Endothelin-1 (ET-1) has been shown to have an important role
in diabetic nephropathy (DN). Here we investigated the contribution
of endothelial cell-derived ET-1 to the changes in renal phenotype
of diabetic mice. Therefore, we induced type 1 diabetes in vascular
endothelial cell-speciﬁc ET-1 knockout (VEETKO) mice and their wild
type (WT) littermates by streptozotocin injection (i.p. 50 mg/kg/day,
ﬁve consecutive days). After ten and 22 weeks of diabetes, we observed
an increase of food and water intake, urine volume and creatinine
clearance in both genotypes compared to non-diabetic mice. The renal
cortical expression of ET-1 mRNA was not signiﬁcantly activated by
diabetes. Nevertheless, VEETKO mice showed only about half of ET-1
mRNA expression compared to WT mice. Though, there were no sig-
niﬁcant differences in the renal function including albumin and protein
excretion between the genotypes. Based on hematocrit measurements,
neither diabetes nor ET-1 deﬁciency had an impact on ﬂuid retention.
After ten weeks of diabetes, systolic blood pressure measured by tail-
cuff method decreased in WT mice. After 22 weeks, heart rate and
systolic and diastolic blood pressurewere similar between all groups. At
baseline the kidneys of VEETKOmicewere signiﬁcantly heavier (+15%)
compared to WT mice but this gap was not observed in diabetic
condition. In contrast to previously presented data, in thismodel of type
1 diabetes we are not able to conﬁrm the pivotal role of endothelial cell
derived ET in the development of DN.
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Background: Endothelin receptor antagonists reduce albuminuria
in diabetic patients. However, adverse effects related to ﬂuid retention
and attributed to the blocking of the tubular endothelin receptors
prevent the use of ERA clinically. The endothelin A (ETA) receptors
on podocytes might be implicated in albuminuria during diabetes.
We hypothesized that the suppression of the ETA receptors on the
podocytes may reduce albuminuria without affecting the tubular func-
tions. Methods and results: To address this question, we generated
podocyte speciﬁc ETA deﬁcient mice using ETA ﬂoxedmice matedwith
mice expressing the Cre recombinase under the control of the nephrin
gene (PodoETAKO mice). We induced type-1 diabetes in seven-week
old male PodoETAKO mice and their wild type (WT) littermates by
streptozotocin injection (i.p. 50 mg/kg/day, ﬁve consecutive days). A set
of animals were treated with macitentan, a dual ETA/ETB antagonist
(25 mg/kg/day, orally, mixed with food). The hyperglycemic mice
developed glomerular hyperﬁltration, renal hypertrophy, reduced serum
creatinine levels, albuminuria, tubular injury, glomerular hypertrophy
and inﬂammation. After 20 weeks of diabetes, the absence of ETA
receptors on podocytes had no effect on these parameters. Macitentan
treatment however reduced albuminuria and restored serum creatinine
levels in wild type mice. Interestingly, the effects of macitentan were
diminished in PodoETAKO mice. Similarly, macitentan increased
podocyte number per glomerulus (WT-1 positive cells) and glomerulus
size in WT but not in PodoETAKO mice. Neither ETA deﬁciency nor
macitentan treatment increased water retentionmeasured as free water
clearance. Conclusion: In contrast to systemic dual ETA/ETB receptor
blockade, the suppression of the ETA receptors on podocytes is not
antialbuminuric in diabetic mice.
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Retinitis pigmentosa (RP) is an inherited retinal disorder char-
acterized by bone spicul pigment in the retina, attenuated retinal
blood vessels and a pale, waxy optic nerve head with early visual
ﬁeld contraction and decrease of the electroretinogram (ERG). Retinal
hemodynamic impairment is still present in early stages of RP and
various hypotheses have been advanced as to a cause. We studied
with multifocal electroretinogram (mfERG) of the macula and optical
coherence tomography (OCT) of the choroid 24 patients, 14 males and
10 females, aged 63–45 yrs. (mean 55 ± 7 yrs.) and affected by simplex
RP. The patients had a visual acuity of 0.1 log MAR with a mean defect
(MD) of the visual ﬁeld of −12.32 ± 8.48 dB, a pattern standard
deviation index (PSD) of 6.09 ± 4.22 dB and a b-wave electroretino-
gram (ERG) amplitude of 45.08 ± 8.24 &muV. An increase of endo-
thelin-1 (ET-1) plasma levels was found: 2.143 ± 0.258 pg/ml vs.
1.219 ± 0.236 pg/ml in non-RP controls (p b 0.002). The choroidal
thickness was 226.75 ± 76.37 μ vs. 303.9 ± 39.87 μ (p b 0.002) in
normal controls. The Spearman's correlation test highlighted that the
decrease of choroidal thickness (r =−0.702; p b 0.023) and the in-
crease of time latency in the rings 2 (r =−0.669; p b 0.034) and 3
(r = -0.883; p b 0.007) of mfERG were related to the increase of ET-1
plasma levels. It is thought that an increase in ET-1 in our RP could lead
to a vasoconstriction in the choroidal vessels and worsening the
abiotrophic process of the macular photoreceptors with increase of the
conduction implicit time.
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Background: Percutaneous coronary intervention (PCI) is often
complicated by post-procedural myocardial necrosis as manifested
by elevated cardiac troponin. Plasma pentraxin 3 (PTX3) levels are
increased in patients with arterial inﬂammation, especially unstable
angina pectoris (AP). The study tested whether plasma PTX3 levels
can predict post-PCI cardiac troponin T (TnT) elevation. Methods:
We evaluated 94 consecutive patients with AP of normal pre-PCI TnT
levels who underwent PCI. Pre-PCI virtual histology-intravascular
ultrasound was performed to assess culprit plaque composition.
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